{"id":"placebo-plus-best-supportive-care","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5278854","moleculeType":null,"molecularWeight":"1243.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a control comparator used in clinical trials, not an active drug. It consists of an inert placebo combined with standard-of-care supportive measures (symptom management, monitoring, etc.). The purpose is to establish a baseline for measuring the true benefit of the investigational drug being tested against it.","oneSentence":"Placebo plus best supportive care provides no active pharmacological intervention, serving as a control arm to evaluate the efficacy of investigational treatments.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:18.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05664737","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-09","conditions":"Anemia","enrollment":189},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT01900743","phase":"PHASE2","title":"Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2013-06-05","conditions":"Sarcoma","enrollment":219},{"nctId":"NCT05469737","phase":"PHASE2, PHASE3","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes","enrollment":230},{"nctId":"NCT05197426","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-01-17","conditions":"Acute Myeloid Leukemia","enrollment":19},{"nctId":"NCT03456063","phase":"PHASE3","title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-24","conditions":"Non-Small-Cell Lung","enrollment":453},{"nctId":"NCT07327034","phase":"PHASE2","title":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","status":"RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2025-06-13","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":141},{"nctId":"NCT04452097","phase":"PHASE1, PHASE2","title":"Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS","status":"WITHDRAWN","sponsor":"Baylx Inc.","startDate":"2026-06-01","conditions":"COVID-19, ARDS, Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT06824064","phase":"PHASE2","title":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2025-01-17","conditions":"Metastatic Colorectal Cancer, Advanced Colorectal Cancer","enrollment":150},{"nctId":"NCT07164443","phase":"PHASE3","title":"A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-02","conditions":"Metastatic Castration-resistant Prostate Neoplasms","enrollment":663},{"nctId":"NCT05413018","phase":"PHASE2","title":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-08-19","conditions":"Leukemia, Myeloid, Acute","enrollment":34},{"nctId":"NCT04644185","phase":"PHASE2, PHASE3","title":"The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19","status":"TERMINATED","sponsor":"Sinocelltech Ltd.","startDate":"2021-03-27","conditions":"Covid19","enrollment":102},{"nctId":"NCT03062358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-27","conditions":"Carcinoma, Hepatocellular","enrollment":453},{"nctId":"NCT02389244","phase":"PHASE2","title":"A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-09","conditions":"Ewing Sarcomas, Chondrosarcomas, Osteosarcomas","enrollment":163},{"nctId":"NCT07138846","phase":"PHASE3","title":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2026-01","conditions":"Advanced Pancreatic Cancer","enrollment":231},{"nctId":"NCT07066098","phase":"PHASE3","title":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-08-04","conditions":"Pancreatic Cancer","enrollment":201},{"nctId":"NCT01757535","phase":"PHASE3","title":"Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-04-24","conditions":"Leukemia, Myeloid, Acute","enrollment":472},{"nctId":"NCT06988566","phase":"NA","title":"Reduced COPD Related Utilization of Healthcare Services and Increased Social Activities by Patients Offered a 24/7 Accessible Telehealth Service Based on the Epital Care Model.","status":"COMPLETED","sponsor":"ECM Klinikken APS","startDate":"2020-09-04","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":184},{"nctId":"NCT04322539","phase":"PHASE3","title":"A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2020-08-12","conditions":"Metastatic Colorectal Cancer, Metastatic Colon Cancer","enrollment":691},{"nctId":"NCT04234685","phase":"NA","title":"Determining the Effectiveness of a New Phototherapy Treatment for the Knee Osteoarthritis","status":"COMPLETED","sponsor":"Jordan Miller, PT, PhD","startDate":"2018-11-08","conditions":"Osteoarthritis, Knee","enrollment":20},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT01566695","phase":"PHASE3","title":"The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-04-26","conditions":"Myelodysplastic Syndrome","enrollment":216},{"nctId":"NCT04743804","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-06-29","conditions":"Thrombotic Microangiopathy","enrollment":16},{"nctId":"NCT01607957","phase":"PHASE3","title":"Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2012-06-17","conditions":"Colorectal Cancer","enrollment":800},{"nctId":"NCT02500043","phase":"PHASE3","title":"Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2016-02-24","conditions":"Refractory Metastatic Gastric Cancer","enrollment":507},{"nctId":"NCT06492941","phase":"PHASE3","title":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-08-12","conditions":"Advanced Pancreatic Cancer","enrollment":142},{"nctId":"NCT04193553","phase":"PHASE2","title":"Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2020-01-17","conditions":"Gastro Intestinal Stromal Tumour","enrollment":77},{"nctId":"NCT04655118","phase":"PHASE2","title":"Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2020-10-22","conditions":"Myelofibrosis, Indolent Systemic Mastocytosis","enrollment":121},{"nctId":"NCT02933801","phase":"PHASE2","title":"ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2017-03-31","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":92},{"nctId":"NCT03342404","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-02-05","conditions":"Thalassemia","enrollment":145},{"nctId":"NCT01830621","phase":"PHASE3","title":"BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2013-05-10","conditions":"Colorectal Carcinoma","enrollment":282},{"nctId":"NCT04552704","phase":"PHASE1, PHASE2","title":"CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study","status":"TERMINATED","sponsor":"Tianhong Li","startDate":"2020-10-30","conditions":"Advanced Malignant Solid Neoplasm","enrollment":3},{"nctId":"NCT04333420","phase":"PHASE2, PHASE3","title":"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"InflaRx GmbH","startDate":"2020-03-31","conditions":"Severe COVID-19 Pneumonia","enrollment":399},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":"Indolent Systemic Mastocytosis","enrollment":140},{"nctId":"NCT02604433","phase":"PHASE3","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-02","conditions":"Erythrocyte Transfusion, Beta-Thalassemia","enrollment":336},{"nctId":"NCT05047783","phase":"PHASE2","title":"Masitinib in Patients With Symptomatic Mild to Moderate COVID-19","status":"UNKNOWN","sponsor":"AB Science","startDate":"2021-11-23","conditions":"Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019","enrollment":78},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":"Mast Cell Activation Syndrome","enrollment":72},{"nctId":"NCT02435433","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-07-20","conditions":"Hepatocellular Carcinoma","enrollment":399},{"nctId":"NCT04052737","phase":"PHASE2","title":"PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Pharmazz, Inc.","startDate":"2018-03-23","conditions":"Alzheimer Disease, Dementia","enrollment":80},{"nctId":"NCT02702401","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-26","conditions":"Hepatocellular Carcinoma","enrollment":413},{"nctId":"NCT03042611","phase":"PHASE3","title":"A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer","status":"COMPLETED","sponsor":"Elevar Therapeutics","startDate":"2017-03-14","conditions":"Gastric Cancer, Gastric Adenocarcinoma","enrollment":460},{"nctId":"NCT02683941","phase":"PHASE3","title":"Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours","status":"TERMINATED","sponsor":"Ipsen","startDate":"2017-03-06","conditions":"Neuroendocrine Tumors in Lung","enrollment":77},{"nctId":"NCT04397718","phase":"PHASE2","title":"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2020-07-06","conditions":"COVID-19","enrollment":96},{"nctId":"NCT01507545","phase":"PHASE2","title":"Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)","status":"TERMINATED","sponsor":"Morphotek","startDate":"2012-03-27","conditions":"Metastatic Colorectal Cancer, Colorectal Cancer","enrollment":154},{"nctId":"NCT02773524","phase":"PHASE3","title":"A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2016-11","conditions":"Gastro-Oesophageal Cancer","enrollment":250},{"nctId":"NCT03905902","phase":"PHASE3","title":"DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma","status":"WITHDRAWN","sponsor":"SOTIO a.s.","startDate":"2021-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT01524783","phase":"PHASE3","title":"Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03-30","conditions":"Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors","enrollment":302},{"nctId":"NCT01767857","phase":"PHASE3","title":"A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-03-31","conditions":"Metastatic Colorectal Cancer","enrollment":643},{"nctId":"NCT01271712","phase":"PHASE3","title":"Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-04","conditions":"Gastrointestinal Stromal Tumors","enrollment":199},{"nctId":"NCT04683328","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2021-02-25","conditions":"Covid19","enrollment":560},{"nctId":"NCT04183478","phase":"PHASE2, PHASE3","title":"The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-26","conditions":"Pancreatic Cancer","enrollment":600},{"nctId":"NCT01774344","phase":"PHASE3","title":"Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05-14","conditions":"Carcinoma, Hepatocellular","enrollment":573},{"nctId":"NCT02196688","phase":"PHASE2","title":"Study of Fruquintinib in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2014-04","conditions":"Colorectal Cancer","enrollment":71},{"nctId":"NCT02314819","phase":"PHASE3","title":"A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2014-12","conditions":"Colorectal Cancer","enrollment":416},{"nctId":"NCT02590965","phase":"PHASE2","title":"A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2014-05-29","conditions":"Non-small Cell Lung Cancer","enrollment":91},{"nctId":"NCT00814073","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-12","conditions":"Indolent Systemic Mastocytosis","enrollment":135},{"nctId":"NCT00825955","phase":"PHASE3","title":"Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-02-17","conditions":"Liver Cancer","enrollment":587},{"nctId":"NCT00917384","phase":"PHASE3","title":"Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Gastric Cancer, Adenocarcinoma","enrollment":355},{"nctId":"NCT01098266","phase":"PHASE3","title":"NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed","status":"COMPLETED","sponsor":"AGC Biologics S.p.A.","startDate":"2010-04-12","conditions":"Malignant Pleural Mesothelioma","enrollment":400},{"nctId":"NCT02008318","phase":"PHASE2, PHASE3","title":"A Study of Galunisertib in Participants With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-03","conditions":"Myelodysplastic Syndromes","enrollment":43},{"nctId":"NCT01287585","phase":"PHASE3","title":"Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy","status":"COMPLETED","sponsor":"Polaris Group","startDate":"2011-07","conditions":"Hepatocellular Carcinoma","enrollment":636},{"nctId":"NCT01707966","phase":"PHASE3","title":"Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":47},{"nctId":"NCT02489149","phase":"NA","title":"Food and Nutrition Education in Quilombolas Communities With Food Insecurity: Multi-sector Intervention","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2015-03","conditions":"Obesity","enrollment":4},{"nctId":"NCT02691299","phase":"PHASE3","title":"A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2015-12-09","conditions":"NSCLC","enrollment":527},{"nctId":"NCT01358084","phase":"PHASE2","title":"Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM","status":"COMPLETED","sponsor":"AGC Biologics S.p.A.","startDate":"2011-03","conditions":"Advanced Malignant Pleural Mesothelioma","enrollment":137},{"nctId":"NCT01210495","phase":"PHASE2","title":"Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12-06","conditions":"Hepatocellular Carcinoma","enrollment":224},{"nctId":"NCT00789373","phase":"PHASE3","title":"A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-11","conditions":"Non-Small Cell Lung Cancer","enrollment":939},{"nctId":"NCT02053311","phase":"PHASE3","title":"Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents","status":"WITHDRAWN","sponsor":"Swiss Cancer Institute","startDate":"2014-08-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT03580239","phase":"PHASE3","title":"Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2019-01-01","conditions":"Prostate Cancer","enrollment":120},{"nctId":"NCT01024036","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03-18","conditions":"Multicentric Castleman's Disease","enrollment":79},{"nctId":"NCT01529112","phase":"PHASE2","title":"A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"Non-Small Cell Lung Cancer","enrollment":135},{"nctId":"NCT02149108","phase":"PHASE3","title":"Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-09-25","conditions":"Colorectal Neoplasms","enrollment":768},{"nctId":"NCT01858571","phase":"PHASE3","title":"Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2013-10","conditions":"Malignant Childhood Neoplasm","enrollment":108},{"nctId":"NCT01015443","phase":"PHASE3","title":"Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-12","conditions":"Non-Small Cell Lung Cancer","enrollment":285},{"nctId":"NCT00508001","phase":"PHASE2","title":"Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-07","conditions":"Carcinoma, Hepatocellular","enrollment":67},{"nctId":"NCT01035229","phase":"PHASE3","title":"Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Carcinoma","enrollment":546},{"nctId":"NCT01964235","phase":"PHASE2","title":"Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12","conditions":"Advanced Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT00656136","phase":"PHASE3","title":"BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":585},{"nctId":"NCT00259064","phase":"PHASE2, PHASE3","title":"Iressa v BSC (Best Supportive Care) in First Line NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"NSCLC","enrollment":216},{"nctId":"NCT01314066","phase":"PHASE2","title":"Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2010-07","conditions":"Severe Sepsis, Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT01658436","phase":"PHASE2","title":"BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Pancreatic Neuroendocrine Tumors (pNET)","enrollment":31},{"nctId":"NCT01584830","phase":"PHASE3","title":"Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-04","conditions":"Colorectal Neoplasms","enrollment":204},{"nctId":"NCT01140347","phase":"PHASE3","title":"A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Hepatocellular Carcinoma","enrollment":565},{"nctId":"NCT00879333","phase":"PHASE3","title":"Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Advanced Gastric Cancer","enrollment":656},{"nctId":"NCT01911273","phase":"PHASE2","title":"A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Carcinoma, Hepatocellular","enrollment":3},{"nctId":"NCT01108705","phase":"PHASE3","title":"Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2010-05","conditions":"Carcinoma, Hepatocellular","enrollment":87},{"nctId":"NCT00510068","phase":"PHASE3","title":"Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Advanced Neuroendocrine Tumors of Pancreatic Origin","enrollment":410},{"nctId":"NCT01103323","phase":"PHASE3","title":"Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04","conditions":"Metastatic Colorectal Cancer","enrollment":760},{"nctId":"NCT00676507","phase":"PHASE3","title":"Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy","status":"COMPLETED","sponsor":"NovaRx Corporation","startDate":"2008-07","conditions":"Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB","enrollment":532},{"nctId":"NCT00102804","phase":"PHASE3","title":"Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-03","conditions":"Non-Small Cell Lung Cancer","enrollment":663},{"nctId":"NCT01513317","phase":"PHASE2","title":"A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-11","conditions":"Myelodysplastic Syndrome","enrollment":76},{"nctId":"NCT00410124","phase":"PHASE3","title":"RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Metastatic Renal Cell Carcinoma","enrollment":416},{"nctId":"NCT00090363","phase":"PHASE2","title":"ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-07","conditions":"Prostate Cancer","enrollment":447},{"nctId":"NCT00688766","phase":"PHASE3","title":"Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib","status":"TERMINATED","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2008-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":47},{"nctId":"NCT00917748","phase":"PHASE3","title":"Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Prostatic Neoplasms, Breast Cancer","enrollment":84},{"nctId":"NCT00707304","phase":"PHASE3","title":"Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Agennix","startDate":"2008-11","conditions":"Non Small Cell Lung Cancer","enrollment":742},{"nctId":"NCT01579188","phase":"PHASE3","title":"Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Kael-GemVax Co., Ltd.","startDate":"2012-05","conditions":"Inoperable Stage III Non-small Cell Lung Cancer","enrollment":600},{"nctId":"NCT00246727","phase":"PHASE3","title":"Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Farm Corporation","startDate":"2005-12","conditions":"Non-small Cell Lung Cancer","enrollment":300},{"nctId":"NCT00242801","phase":"PHASE3","title":"Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-07","conditions":"NSCLC","enrollment":1692}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":111,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo plus best supportive care","genericName":"Placebo plus best supportive care","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}